Burney Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.46M Buy
25,296
+588
+2% +$33.8K 0.04% 294
2026
Q1
$1.5M Sell
24,708
-38,913
-61% -$2.27M 0.05% 263
2025
Q4
$3.43M Buy
63,621
+53,141
+507% +$2.56M 0.11% 174
2025
Q3
$473K Sell
10,480
-312
-3% -$14.6K 0.02% 425
2025
Q2
$500K Sell
10,792
-1,576
-13% -$77.4K 0.02% 413
2025
Q1
$754K Sell
12,368
-385
-3% -$22.4K 0.03% 340
2024
Q4
$721K Buy
12,753
+516
+4% +$28.8K 0.03% 363
2024
Q3
$633K Sell
12,237
-1,534
-11% -$72K 0.02% 400
2024
Q2
$572K Sell
13,771
-345
-2% -$15.4K 0.02% 399
2024
Q1
$766K Sell
14,116
-347
-2% -$17.7K 0.03% 364
2023
Q4
$742K Sell
14,463
-10,703
-43% -$562K 0.03% 364
2023
Q3
$1.46M Sell
25,166
-34,140
-58% -$2.09M 0.07% 262
2023
Q2
$3.79M Buy
59,306
+46,858
+376% +$3.14M 0.17% 153
2023
Q1
$863K Buy
12,448
+20
+0.2% +$1.41K 0.04% 336
2022
Q4
$894K Sell
12,428
-230
-2% -$17.3K 0.05% 312
2022
Q3
$900K Sell
12,658
-67
-0.5% -$4.86K 0.05% 317
2022
Q2
$980K Sell
12,725
-400
-3% -$30.5K 0.05% 305
2022
Q1
$959K Sell
13,125
-221
-2% -$14.8K 0.04% 333
2021
Q4
$832K Sell
13,346
-549
-4% -$32.2K 0.04% 355
2021
Q3
$822K Buy
13,895
+184
+1% +$12.1K 0.04% 338
2021
Q2
$916K Sell
13,711
-154
-1% -$10K 0.04% 330
2021
Q1
$875K Buy
13,865
+876
+7% +$54.5K 0.04% 325
2020
Q4
$806K Sell
12,989
-1,764
-12% -$108K 0.04% 312
2020
Q3
$890K Sell
14,753
-11,260
-43% -$678K 0.06% 291
2020
Q2
$1.53M Sell
26,013
-12,093
-32% -$723K 0.1% 225
2020
Q1
$2.12M Sell
38,106
-66,469
-64% -$4.06M 0.16% 160
2019
Q4
$6.71M Buy
104,575
+96,446
+1,186% +$5.52M 0.37% 89
2019
Q3
$412K Sell
8,129
-496
-6% -$23.3K 0.02% 334
2019
Q2
$391K Sell
8,625
-1,000
-10% -$46.6K 0.02% 353
2019
Q1
$459K Sell
9,625
-380
-4% -$18.9K 0.03% 330
2018
Q4
$520K Buy
10,005
+894
+10% +$48K 0.04% 304
2018
Q3
$566K Sell
9,111
-4,228
-32% -$251K 0.03% 312
2018
Q2
$738K Sell
13,339
-214
-2% -$11.6K 0.04% 282
2018
Q1
$857K Sell
13,553
-1,049
-7% -$67.5K 0.05% 254
2017
Q4
$895K Buy
14,602
+1,150
+9% +$71.9K 0.05% 254
2017
Q3
$848K Sell
13,452
-8,212
-38% -$479K 0.06% 244
2017
Q2
$1.21M Buy
21,664
+5,735
+36% +$312K 0.08% 209
2017
Q1
$866K Buy
15,929
+8,175
+105% +$448K 0.06% 231
2016
Q4
$453K Sell
7,754
-572
-7% -$31.3K 0.03% 269
2016
Q3
$459K Buy
8,326
+577
+7% +$37.1K 0.03% 268
2016
Q2
$570K Sell
7,749
-72
-0.9% -$5.09K 0.04% 246
2016
Q1
$500K Sell
7,821
-535
-6% -$33.7K 0.04% 272
2015
Q4
$578K Hold
8,356
0.04% 241
2015
Q3
$495K Buy
8,356
+524
+7% +$33.2K 0.04% 253
2015
Q2
$521K Sell
7,832
-835
-10% -$55K 0.04% 267
2015
Q1
$559K Buy
8,667
+100
+1% +$6.26K 0.04% 272
2014
Q4
$506K Sell
8,567
-600
-7% -$33.8K 0.04% 272
2014
Q3
$469K Buy
9,167
+295
+3% +$14.7K 0.04% 277
2014
Q2
$430K Buy
8,872
+100
+1% +$4.93K 0.04% 296
2014
Q1
$456K Sell
8,772
-889
-9% -$47.3K 0.04% 280
2013
Q4
$513K Sell
9,661
-629
-6% -$32K 0.05% 274
2013
Q3
$476K Sell
10,290
-2,734
-21% -$120K 0.05% 276
2013
Q2
$582K Buy
+13,024
New +$565K 0.07% 237

Other funds holding BMY

Burney Company's BMY Position: Q2 2026 in Review

Burney Company increased its Bristol-Myers Squibb (BMY) stake by 2.4% in Q2 2026, buying an estimated $33.8K and bringing the position to 25,296 shares worth $1.46M. The position accounts for 0.04% of the portfolio, ranked #294.

Burney Company first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.71M in Q4 2019. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Burney Company held 25,296 shares of Bristol-Myers Squibb worth $1.46M as of Q2 2026.
  • Burney Company bought 588 Bristol-Myers Squibb shares in Q2 2026, an estimated $33.8K.
  • Bristol-Myers Squibb made up 0.04% of Burney Company's portfolio in Q2 2026, its #294 holding.
  • Burney Company first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Burney Company's Bristol-Myers Squibb position peaked at $6.71M in Q4 2019.
  • 879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Burney Company's 13F filing for Q2 2026, filed 15 Jul 2026.